In collaboration with Principal Investigator Dr. Ana Pereira of Mt. Sinai Hospital and Rockefeller University, ADMdx has published the results of a Phase 2 study of the drug Riluzole in Alzheimer’s disease patients. Patients who received Riluzole for 6 months showed less decline in glucose metabolism, a measure of brain function, in key regions affected by Alzheimer’s disease than those who received placebo. ADMdx led the analysis of the FDG PET brain scans that measured glucose metabolism, which also showed a relationship to measures of cognition. The manuscript, published in the journal Brain, may be found at https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awab222/6305835?guestAccessKey=f5f0e25a-0b66-4625-b964-a955ec834d56.